Document is current
Any future updates will be listed below
-
Authors
Holmström, Morten O. https://orcid.org/0000-0002-3764-8578
Ahmad, Shamaila M.
Klausen, Uffe
Bendtsen, Simone K.
Martinenaite, Evelina
Riley, Caroline H.
Svane, Inge M.
Kjær, Lasse
Skov, Vibe
Ellervik, Christina
Pallisgaard, Niels
Hasselbalch, Hans C.
Andersen, Mads H.
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R149-A10159-B120)
- License Information
-
More Information
Article History
Received: 23 October 2018
Revised: 26 November 2018
Accepted: 30 November 2018
First Online: 17 January 2019
Conflict of interest
: It should be noted that Morten Orebo Holmström, Hans Carl Hasselbalch, and Mads Hald Andersen have filed a patent regarding the <i>CALR</i> exon 9 mutations as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to Danish Law concerning inventions made at public research institutions. The other authors declare that they have no conflict of interest.
